10-K: Elicio Therapeutics Reports Annual Results, Outlines Key Milestones for 2025

Elicio Therapeutics details its financial performance for 2024 and highlights the expected Q3 2025 interim analysis of its Phase 2 AMPLIFY-7P trial.

Summary

• Elicio Therapeutics, a clinical-stage biotechnology company, released its 10-K filing detailing its 2024 financial results and providing updates on its clinical programs.
• The company is focused on developing immunotherapies targeting lymph nodes to treat cancers with specific oncogenic driver mutations.
• Elicio's lead product candidate, ELI-002, is currently in a Phase 2 trial (AMPLIFY-7P) for pancreatic ductal adenocarcinoma (PDAC), with an interim analysis expected in Q3 2025.
• The company completed enrollment in the AMPLIFY-7P trial in December 2024 and will follow patients for up to 36 months.
• The company incurred a net loss of $51.9 million in 2024, compared to a net loss of $35.2 million in 2023.
• As of December 31, 2024, Elicio had $17.6 million in cash and cash equivalents, which it believes will fund operations into the fourth quarter of 2025.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern.
• Elicio is seeking additional funding through various means, including equity offerings, debt financing, and strategic collaborations.
• The company is also advancing preclinical programs ELI-007 and ELI-008, targeting BRAF and TP53 mutations, respectively.
• Elicio is exploring collaborations to capitalize on its AMP technology in areas like infectious disease vaccines and CAR-T cell therapies.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials, the company's financial situation raises concerns about its ability to continue as a going concern. The increased net loss and dependence on raising additional capital contribute to a negative outlook.

Positives

• ELI-002 is in Phase 2 clinical trials with an expected interim analysis in Q3 2025.
• The company has completed enrollment in the AMPLIFY-7P trial.
• The company is advancing preclinical programs ELI-007 and ELI-008.
• Elicio is exploring collaborations to capitalize on its AMP technology in areas like infectious disease vaccines and CAR-T cell therapies.

Negatives

• The company incurred a net loss of $51.9 million in 2024.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company is dependent on raising additional capital.
• Clinical trial results may not support regulatory approval.
• The company faces significant competition.
• The company relies on third-party manufacturers.
• The company's technology is novel and may be difficult to manufacture.
• The company is dependent on intellectual property licensed from MIT.
• The company may be subject to product liability claims.
• The company may be subject to cybersecurity incidents.

Future Outlook

Elicio anticipates that its existing cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of 2025. The company plans to continue advancing ELI-002, expand its clinical development, and advance its internal pipeline.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition, and strong defense of intellectual property. Elicio faces competition from major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.

Comparison to Industry Standards

• Amgen Inc.'s LUMAKRAS and Mirati Therapeutics, Inc.'s KRAZATI are approved therapies for NSCLC with a single KRAS mutation, indicating a competitive landscape in mKRAS-associated cancer treatment.
• AstraZeneca Plc, BioNTech SE, and Moderna, Inc. are developing clinical-stage personalized cancer vaccine therapies or mKRAS-targeted therapies, showcasing the industry's focus on immunotherapy.
• Many competitors have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than Elicio does.

Corporate Governance

Related Party Transactions

• Yekaterina (Katie) Chudnovsky, a member of the board of directors, and GKCC, LLC (GKCC), an entity controlled by Ms. Chudnovsky, together beneficially own 34.1% of our outstanding common stock.
• In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Companys board of directors, for purposes of the March Offering.
• In August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0 million pursuant to the Note Financing.
• Jay Venkatesan, a member of the Companys board of directors, and trusts affiliated with Jay Venkatesan, purchased 200,000 July Pre-Funded Warrants and accompanying July Common Warrants, respectively, with such July Pre-Funded Warrants and July Common Warrants subject to the terms and conditions of the July Pre-Funded Warrants and July Common Warrants.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if the company is unable to raise additional capital.
• Patients may benefit from the continued development of Elicio's product candidates.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Continue advancing ELI-002 in the ongoing Phase 2 trial in PDAC.
• Expand ELI-002 clinical development for the treatment of other KRAS driven cancers.
• Advance development of the internal pipeline, including ELI-007 and ELI-008, for additional oncology targets.
• Realize the full value of the AMP technology through collaborations.

Key Dates

Keywords

ELI-002, AMP technology, immunotherapy, KRAS, clinical trials, biotechnology, cancer, Elicio Therapeutics, financial results